Introduction
============

The management of acute coronary syndromes (ACS) is constantly evolving with new therapies and interventions tested in clinical trials. Subjects with ST elevation myocardial infarction (STEMI) are at very high early risk, and timely reperfusion therapy with thrombolysis or primary angioplasty substantially reduces mortality.[@b1] [@b2] In patients with non-ST elevation syndromes (NSTEMI), an early invasive strategy with revascularisation where appropriate is recommended by international societies and supported by several prospective trials.[@b3; @b4; @b5] This strategy is particularly beneficial in patients deemed to be at high risk---specifically those patients with elevated cardiac biomarkers or dynamic ECG changes.[@b6] Age in isolation has been considered a risk factor for patients presenting with ACS yet a paradox exists that elderly patients \>75 years are frequently under-represented in clinical trials, whereas in clinical practice, they constitute a significant proportion of the patient population.[@b7] [@b8]

A poor outcome in the elderly population may be associated with more complex coronary disease, increased comorbidity and higher risk of complication from revascularisation procedures.[@b9; @b10; @b11] Despite this, recent studies and large international registries have shown that the elderly population have substantially improved outcome with early invasive management, yet compared to younger patients an interventional strategy is less likely to be offered.[@b5] [@b12; @b13; @b14; @b15; @b16; @b17]

The objective of this study was to assess the management of ACS in an elderly population using data taken from a national registry. Specifically, we planned to test the hypothesis that age in isolation does not adversely affect the outcome of patients presenting with ACS who are managed with an early interventional strategy and coronary revascularisation. We also explored the reasons that some elderly patients are not considered appropriate for an early invasive strategy.

Methods
=======

The Acute Coronary Syndrome Prospective Audit (ACACIA, protocol number PM_L\_0051) is a registry of Australian practice collected between 1 November 2005 and 31 July 2007 involving 39 hospitals across all states and territories of Australia. These sites were selected to be representative of rural (25%) and metropolitan (75%) centres, interventional (83%) and non-interventional (17%) centres and 52% of sites reported onsite cardiac surgery. Each site sought consecutive enrolment of between 100 and 150 patients admitted from the local emergency service for suspected ACS (median, 99). Patients presenting with ACS thought to be secondary to major trauma or surgery were excluded. Patients transferred into study centres were excluded if more than 12 h had passed since their initial presentation to enable more accurate assessment of immediate care.

Ethics approval was obtained from all sites, and written informed consent was obtained from all conscious patients. Access to medical records was permitted.

Definition of ACS and data collection
-------------------------------------

Patients presenting with suspected STEMI or NSTEMI were eligible for enrolment. The primary discharge diagnosis was determined by the investigators at each site but was confirmed by a central adjudication process. Stratification of data collection diagnoses was also centrally adjudicated to ensure consistency of enrolment from each centre. Allocation to non-cardiac chest pain was made when ACS was excluded or a positive alternative diagnosis was made, data from these patients were not included in the principle analyses. Standard clinical data were recorded including type and results of all investigations and medications. Early interventional strategy was defined as angiography at any point during the index acute admission, including emergency primary per-cutaneous intervention (PCI) for STEMI but excluded outpatient angiography. The use, time and extent of revascularisation by angioplasty (PCI) or surgery (coronary artery bypass surgery, CABG) was recorded. All data were collated by trained research coordinators. All-cause mortality was determined during the index admission and at 12 months. Any patients lost to follow-up were referred as a query to the Australian Institute of Health and Welfare National Death Register to confirm status and cause of death. Data on non-fatal vascular events further revascularisation and unplanned hospital readmissions were recorded from hospital records and discharge codes.

Statistics
----------

Primary outcome was all-cause mortality at 12 months. Secondary outcomes were thrombolysis in myocardial infarction (TIMI) bleeding at 30 days and a composite of subsequent myocardial infarction, stroke, death and cardiovascular cause for unplanned hospital readmission at 12 months. We defined the elderly population as those patients older than 75 years, this value was selected since patients of this age and above have frequently been excluded from prospective clinical trials. Categorical outcomes and parameters were analysed with χ^2^ analysis or Fisher\'s exact test for 2×2 comparisons. Multivariate analysis of event-free survival and overall survival was performed using Cox proportional hazard. Survival curves were plotted to examine the effect of an early invasive strategy in the aged cohort. Binary logistic regression was used to evaluate time-independent outcomes. To evaluate the impact of an early invasive strategy on 12 month mortality in patients \>75 years and to control for substantial confounding clinical factors associated with increased age, a propensity analysis was performed using a non-parsimonious logistic regression model including age \>75 years, gender, indigenous status, Killip class, GRACE score, cardiac arrest, normal ECG, ST segment depression or elevation, shock, pulmonary oedema or arrhythmia; presence of renal replacement therapy, dyslipidaemia, hypertension, diabetes, chronic airways disease, peripheral vascular disease, malignancy or atrial fibrillation; history of coronary artery disease, myocardial infarction, PCI, CABG or stroke (c-index: 0.89). A logistic regression model for survival until 12 months including age, propensity score and early invasive management was then undertaken. This model was used to predict the expected mortality in ascending strata of age groups. These data are presented across the age groups further stratified by use of early invasive management. All data were analysed using commercially available software STATA V.13. Significance was sought at the 5% level.

Results
=======

Baseline characteristics
------------------------

A total of 3402 patients were enrolled, and vital status was available for 3393 at 1 year. Discharge diagnosis of STEMI was recorded in 717 patients, NSTEMI in 1027 and unstable angina in 815 giving a study population of 2559. Patients excluded from analyses (843) were assigned to a variety of non-ACS diagnoses (including but not exclusive to: musculoskeletal chest pain, pericarditis, respiratory infection and pulmonary embolism). Elderly patients, \>75 years comprised 27% (n=683) of the study population, baseline variables are shown in [table 1](#tbl1){ref-type="table"}. The younger group were more likely to be active smokers and to present with cardiac arrest. The elderly group presented more frequently in association with haemodynamic disturbance and other comorbidity.

###### 

Baseline characteristics

  Variable                               \<75 years (N=1876)   \%    \>75 years (N=683)   \%    χ^2^ (Fisher\'s)
  -------------------------------------- --------------------- ----- -------------------- ----- ------------------
  Male                                   1380                  74    372                  55    0.001
  Dyslipidaemia                          1134                  60    418                  61    0.7
  Current smoker                         570                   30    34                   5     0.001
  Known coronary disease                 851                   45    438                  64    0.001
  Previous MI                            479                   26    251                  37    0.001
  Chronic heart failure                  93                    5     121                  18    0.001
  Previous PCI                           356                   19    123                  18    0.3
  Previous CABG                          234                   12    150                  22    0.001
  Diabetes                               512                   27    171                  25    0.25
  Hypertension                           1125                  60    510                  75    0.001
  Atrial fibrillation                    137                   7     139                  20    0.001
  Peripheral vascular disease            82                    4     80                   12    0.001
  Malignancy                             96                    5     84                   12    0.001
  Elevated cardiac biomarkers            1384                  74    485                  71    0.163
  Normal ECG                             506                   27    155                  23    0.03
  ST segment deviation (including BBB)   894                   48    338                  50    0.4
  ST elevation                           577                   31    138                  20    0.001
  ST depression                          224                   12    123                  18    0.001
  Left bundle branch block               73                    4     72                   11    0.001
  Killip 1                               1589                  85    448                  66    0.001
  Pulmonary oedema                       72                    4     60                   9     0.001
  Cardiac arrest                         68                    3.6   11                   1.6   0.009
  Arrhythmia on presentation             115                   6     40                   6     0.8

BBB, bundle branch block; CABG, coronary artery bypass surgery; MI, myocardial infarction; PCI, per-cutaneous intervention.

In hospital management
----------------------

During in hospital care, the elderly group were less likely to be treated with evidence-based medical therapies and were less frequently referred for angiography (79% vs 49%, p=0.0001) ([table 2](#tbl2){ref-type="table"}). Revascularisation as a whole was therefore less frequently performed in the elderly cohort. The disparity in revascularisation was driven primarily by less frequent referral for diagnostic angiogram. If angiography was performed, then the rates of revascularisation were more comparable (61% vs 66%, p=0.04). Logistic regression of the whole cohort identified 13 variables that independently contributed to mortality at 12 months ([figure 1](#fig1){ref-type="fig"}). Among these variables, an age \>75 years increased mortality risk (OR 1.7 (95% CI 1.2--2.6)) and early revascularisation reduced risk (OR 0.4 (95% CI 0.2--0.7)). Division of the data into subjects older than 75 years found early revascularisation to remain highly protective in terms of risk of all-cause mortality (OR 0.4 (95% CI 0.2--0.7)) and composite outcome (OR 0.6 (95% CI 0.5--0.8)) ([figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Predicted mortality based on the propensity model suggested further benefit associated with early revascularisation and incrementally greater benefit was projected in the higher age brackets ([figure 4](#fig4){ref-type="fig"}). We explored the factors associated with for non-referral for angiogram and for not performing revascularisation. Independent variables that appeared to contribute to non-referral for angiogram included age over 75 years, female gender, presence of diabetes and history of myocardial infarction ([figure 5](#fig5){ref-type="fig"}). Once an angiogram had been performed, fewer variables influenced the decision to perform revascularisation and neither gender nor age \>75 years was contributory.

###### 

In hospital management

  Variable                                                    \<75 years (N=1876)   \%    \>75 years (N=683)   \%     p Value
  ----------------------------------------------------------- --------------------- ----- -------------------- ------ ------------------------------------------
  Aspirin                                                     1672                  89    528                  77     0.001
  Clopidogrel                                                 1234                  66    357                  52     0.001
  2b3a Agent                                                  163                   8.7   36                   5      0.004
  Low-molecular-weight heparin                                1410                  75    520                  76.1   0.6
  Angiotensin-converting enzyme inhibitor                     1110                  59    370                  54     0.02
  Angiotensin receptor antagonist                             243                   13    116                  17     0.009
  HMG-CoA enzyme inhibitor                                    1635                  87    537                  79     0.001
  B-blocker                                                   1346                  72    446                  65     0.002
  Functional test for ischaemia                               188                   10    43                   6.3    0.004
  Diagnostic angiography                                      1401                  75    335                  49     0.001
  Echocardiogram                                              758                   40    293                  42     0.26
  Angioplasty                                                 808                   43    169                  25     0.001
  Coronary surgery                                            154                   8.2   46                   6.7    0.2
  Revascularisation if angiogram                              931 from 1401         66    203 from 335         61     0.04
  Reperfusion if (STEMI)                                      420                   72    80                   60     0.008
  Primary PCI                                                 256                   44    50                   38     0.2
  Rescue PCI                                                  33                    6     2                    1.5    0.05
  TIMI bleed                                                  83                    4     34                   5      0.5
  Time to diagnostic angiogram (days) excluding primary PCI   1.02±4.5                    2.6±4.0                     0.5[\*](#table-fn1){ref-type="table-fn"}
  Time to primary PCI (minutes)                               180.7±42.1                  123±61.4                    0.3[\*](#table-fn1){ref-type="table-fn"}

χ^2^ Statistic unless stated.

Unpaired t test.

PCI, per-cutaneous intervention; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.

![Box plot indicating HR contributing to all-cause mortality at 1 year in acute coronary syndromes cohort in multivariate analysis. ACE, angiotensin converting enzyme inhibitor; ARA, angiotensin receptor antagonist; CHF, chronic heart failure; eREVASC, early revascularisation within the index admission; PCI, per-cutaneous intervention.](bmjopen-2011-000540fig1){#fig1}

![Survival curve of elderly acute coronary syndromes cohort with respect to early revascularisation.](bmjopen-2011-000540fig2){#fig2}

![Freedom from composite outcome in elderly acute coronary syndromes cohort with respect to early revascularisation. CVA, cerebrovascular accident (stroke); MI, myocardial infarction.](bmjopen-2011-000540fig3){#fig3}

![Predicted absolute mortality (error bars are SD) at 1 year calculated from propensity model.](bmjopen-2011-000540fig4){#fig4}

![Box plot indicating HR contributing to likelihood of referral for diagnostic coronary angiography in the acute coronary syndromes cohort. AF, atrial fibrillation; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PCI, per-cutaneous intervention; STEMI, ST elevation myocardial infarction.](bmjopen-2011-000540fig5){#fig5}

TIMI bleeding
-------------

There were 123 episodes of TIMI bleeding in the study cohort within 30 days of index presentation. Overall, age \>75 years was not a risk factor for bleeding (HR 1.3 (0.86--1.9)) nor was there excess bleeding in the old versus younger cohorts (5% vs 4%, p=0.6). Early revascularisation was associated with a substantially higher risk of bleeding in both the young (10.5 (5.1--21)) and aged (14.9 (5.6--40)) cohort, and this relationship was independent of the use of aspirin, clopidogrel and anticoagulation at the time of presentation. Comparison limited to the patients who received early revascularisation (n=1134) did reveal excess bleeding in the aged cohort compared to the younger group (13.2% vs 7.6%, p=0.01).

Discussion
==========

The ACACIA data set provides an outstanding insight into the management of ACS sourcing data from different types of hospital. These data in concordance with other studies show that elderly patients are more often managed conservatively, a particular barrier appears to be at the level of referral for diagnostic angiogram with less than half of the patients \>75 years receiving this investigation. This observation is not a new finding[@b12] [@b18] and provides some evidence of referral bias; most young patients are offered an angiogram, whereas most elderly patients are not. Unfortunately, our data do not record the reason for this disparity since we do not have data on generalised extreme frailty, patient choice or a positive decision to palliate patients based on extensive comorbidity. There is no doubt that frailty may influence decision to treat individual patients conservatively,[@b19] but it is extremely unlikely that these factors alone account for the fewer number or elderly patients offered an early invasive strategy. The reason for the apparent reluctance of clinicians to offer invasive management to some of their elderly patients is not clear. An obvious observation is that increased age is associated with mortality, yet the effect of age \>75 years was less influential on mortality risk than presence of diabetes, heart failure and haemodynamic disturbance on presentation. Another possibility is the perceived risk of bleeding, we did observe a higher rate of TIMI bleeding at 30 days in the elderly cohort, although this effect did not translate to a change of mortality or composite outcome at 12 months. Furthermore, in our adjusted analysis, the absolute benefit of early revascularisation was positively associated with increased stratifications of age. This analysis is unsurprising since those patients at highest risk (such as the elderly) stand to gain most from an early invasive strategy, and this fact is consistent with the substantial impact of age on risk in scores, such as the GRACE score.[@b20] The phenomenon of elderly patients deriving a greater absolute benefit than younger patients has previously been reported in subgroup analyses of the TACTICS TIMI 18 trial[@b16] and from the crusade registry.[@b17] The data from the ACACIA registry reinforce the message of these trials and other data demonstrating that age is not a bar to the benefits associated with invasive management and increased age should not be the dominant factor when contemplating management following hospitalisation with ACS. In the real world, some patients elect not to pursue an early invasive strategy, and this choice may be made more frequently by elderly patients, who may have concerns about their own frailty and long-term morbidity. Physicians may also judge that a patient has such substantial comorbidity that a palliative or limited approach should be undertaken.[@b21] Despite these case-specific management decisions, it is clear from our data, however, that the elderly ACS population are underinvestigated and undertreated, and this may deny these patients the substantial benefit that is seen within 12 months. We encourage all physicians who manage patients with ACS to avoid using advanced age as reason to manage some patients conservatively.

Conclusions
===========

Elderly patients comprise a large group of the ACS population. Despite having higher baseline risk, they are less likely to be offered evidence-based medical therapies and substantially less likely to be investigated invasively with a view to early revascularisation. The effect of an early invasive strategy with revascularisation was associated with improvements in survival and in the composite outcome of myocardial infarction, stroke, death and cardiovascular cause for readmission, at the expense of a higher incidence of TIMI bleeding. Adjustment for baseline covariates using a propensity model suggested greater absolute benefit in patients at advanced age.

Limitations
-----------

The ACACIA data represent a real-world registry; individual decisions on patient management such as reasons for not offering an early invasive strategy were not recorded. Hence, the issue of residual selection bias leading to confounding cannot be fully accounted for. While other techniques such as 'instrument variable analysis' offer alternative approaches to this problem, determining a viable instrument remains challenging. Nevertheless, these data are consistent with other reported literature. Since there was no randomisation process in this registry data, all statistical relationships are reported as associations rather than implied causation.

The geographical challenges of healthcare in Australia are reflected in some of the data such as persisting use of thrombolysis and rescue or convalescent angioplasty. Our data include all patients diagnosed ACS including those with ST elevation myocardial infarction; we did not exclude these patients from analyses since the main interest of the paper was on the impact on age overall, rather than an analysis of a select population of ACS. Our data, therefore, differ from the other major studies of age on outcome that were limited to non-ST elevation myocardial infarctions.[@b5] [@b17] [@b18]

Transfer from a non-interventional centre to an interventional centre was positively associated with an early invasive strategy. It is possible that further referral bias occurs at this level since cardiologists may preselect those patients in whom they expect the best outcomes, especially if transfer involves air travel. However, our data were carefully selected to be representative of real-world cardiology practice including both metropolitan surgical centres and rural district hospitals and evidence of bias in referral based on age or transfer is worthy of discussion.
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